Phosphorylation of AKT(Ser473) serves as an independent prognostic marker for radiosensitivity in advanced head and neck squamous cell carcinoma

International Journal of Cancer

Volumn 136, Issue 12, 2015, Pages 2775-2785

  Freudlsperger, Christian ^a   Horn, Dominik ^a   Weißfuß, Sebastian ^a   Weichert, Wilko ^a   Weber, Klaus Josef ^b   Saure, Daniel ^b   Sharma, Sarika ^a   Dyckhoff, Gerhard ^a   Grabe, Niels ^b,c   Plinkert, Peter ^a   Hoffmann, Jürgen ^a   Freier, Kolja ^a   Hess, Jochen ^a,c  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

AKT; ex vivo; HNSCC; mTOR; PI3K; radiosensitivity; tissue culture; TMA

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SERINE; SERINE 473; UNCLASSIFIED DRUG; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; ENZYME INHIBITOR; MORPHOLINE DERIVATIVE; THREONINE; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DAMAGE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ENZYME ASSAY; ENZYME PHOSPHORYLATION; EX VIVO STUDY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PARACRINE SIGNALING; PREMEDICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; TISSUE LEVEL; TUMOR MICROENVIRONMENT; ADULT; AGED; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; DRUG EFFECTS; HEAD AND NECK NEOPLASMS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PHOSPHORYLATION; RADIATION DOSE; RADIATION RESPONSE; SURVIVAL; TISSUE CULTURE TECHNIQUE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CHROMONES; ENZYME INHIBITORS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MORPHOLINES; MULTIVARIATE ANALYSIS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION TOLERANCE; SERINE; SURVIVAL ANALYSIS; THREONINE; TISSUE CULTURE TECHNIQUES; TUMOR MARKERS, BIOLOGICAL;

EID: 84927553417     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29328     Document Type: Article

References (42)

1. Kamangar F, Dores GM, Anderson WF,. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-50.
2. Vermorken JB, Specenier P,. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol 2010; 21 Suppl 7: vii252-61.
3. Mao L, Hong WK, Papadimitrakopoulou VA,. Focus on head and neck cancer. Cancer Cell 2004; 5: 311-6.
4. Forastiere A, Koch W, Trotti A, Sidransky D,. Head and neck cancer. N Engl J Med 2001; 345: 1890-900.
5. Hildebrandt MA, Lippman SM, Etzel CJ, et al. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clin Cancer Res 2012; 18: 3705-13.
6. Li B, Yuan M, Kim IA, et al. Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin. Oncogene 2004; 23: 4594-602.
7. Freudlsperger C, Burnett JR, Friedman JA, et al. EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opin Ther Targets 2011; 15: 63-74.
8. Molinolo AA, Amornphimoltham P, Squarize CH, et al. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 2009; 45: 324-34.
9. Gupta AK, McKenna WG, Weber CN, et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 2002; 8: 885-92.
10. Vanhaesebroeck B, Alessi DR,. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 2000; 346 Pt 3: 561-76.
11. Tsurutani J, Fukuoka J, Tsurutani H, et al. Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol 2006; 24: 306-14.
12. Gallay N, Dos Santos C, Cuzin L, et al. The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia 2009; 23: 1029-38.
13. Mannino M, Chalmers AJ,. Radioresistance of glioma stem cells: intrinsic characteristic or property of the 'microenvironment-stem cell unit'? Mol Oncol 2011; 5: 374-86.
14. Witz IP,. The tumor microenvironment: the making of a paradigm. Cancer Microenviron 2009; 2 Suppl 1: 9-17.
15. McAllister SS, Weinberg RA,. Tumor-host interactions: a far-reaching relationship. J Clin Oncol 2010; 28: 4022-8.
16. Mbeunkui F, Johann DJ,. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol 2009; 63: 571-82.
17. Franke TF, Hornik CP, Segev L, et al. PI3K/Akt and apoptosis: Size matters. Oncogene 2003; 22: 8983-98.
18. Shaw RJ, Cantley LC,. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441: 424-30.
19. Guyot C, Combe C, Clouzeau-Girard H, et al. Specific activation of the different fibrogenic cells in rat cultured liver slices mimicking in vivo situations. Virchows Arch 2007; 450: 503-12.
20. Vaira V, Fedele G, Pyne S, et al. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci USA 2010; 107: 8352-6.
21. Freier K, Joos S, Flechtenmacher C, et al. Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma. Cancer Res 2003; 63: 1179-82.
22. Karst AM, Dai DL, Cheng JQ, Li G,. Role of p53 up-regulated modulator of apoptosis and phosphorylated Akt in melanoma cell growth, apoptosis, and patient survival. Cancer Res 2006; 66: 9221-6.
23. Ongkeko WM, Altuna X, Weisman RA, Wang-Rodriguez J,. Expression of protein tyrosine kinases in head and neck squamous cell carcinomas. Am J Clin Pathol 2005; 124: 71-6.
24. Massarelli E, Liu DD, Lee JJ, et al. Akt activation correlates with adverse outcome in tongue cancer. Cancer 2005; 104: 2430-6.
25. Lim J, Kim JH, Paeng JY, et al. Prognostic value of activated Akt expression in oral squamous cell carcinoma. J Clin Pathol 2005; 58: 1199-205.
26. Morin PJ,. Drug resistance and the microenvironment: nature and nurture. Drug Resist Updat 2003; 6: 169-72.
27. Sun Y, Nelson PS,. Molecular pathways: involving microenvironment damage responses in cancer therapy resistance. Clin Cancer Res 2012; 18: 4019-25.
28. Weaver VM, Lelièvre S, Lakins JN, et al. beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2002; 2: 205-16.
29. Zhang X, Wang W, Yu W, et al. Development of an in vitro multicellular tumor spheroid model using microencapsulation and its application in anticancer drug screening and testing. Biotechnol Prog 2005; 21: 1289-96.
30. Nakajima K, Okita Y, Matsuda S,. Sensitivity of scirrhous gastric cancer to 5-fluorouracil and the role of cancer cell-stromal fibroblast interaction. Oncol Rep 2004; 12: 85-90.
31. Fallica B, Maffei JS, Villa S, et al. Alteration of Cellular Behavior and Response to PI3K Pathway Inhibition by Culture in 3D Collagen Gels. PLoS ONE 2012; 7: e48024.
32. Schmidt-Ullrich RK, Valerie K, et al. Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. Radiat Res 1996; 145: 81-5.
33. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 1997; 15: 1191-7.
34. Dent P, Reardon DB, Park JS, et al. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 1999; 10: 2493-506.
35. Contessa JN, Hampton J, Lammering G, et al. Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene 2002; 21: 4032-41.
36. Stucki M, Clapperton JA, Mohammad D, et al. MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. Cell 2005; 123: 1213-26.
37. Herzog A, Bian Y, Vander Broek R, et al. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer. Clin Cancer Res 2013; 19: 3808-19.
38. Bussink J, van der Kogel AJ, Kaanders JH,. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 2008; 9: 288-96.
39. Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006; 12: 5064-73.
40. Loeffler-Ragg J, Schwentner I, Sprinzl GM, Zwierzina H,. EGFR inhibition as a therapy for head and neck squamous cell carcinoma. Expert Opin Investig Drugs 2008; 17: 1517-31.
41. Mukherjee B, McEllin B, Camacho CV, et al. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res 2009; 69: 4252-9.
42. Lammering G, Hewit TH, Valerie K, et al. EGFRvIII-mediated radioresistance through a strong cytoprotective response. Oncogene 2003; 22: 5545-53.